Skip to main content

REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1469096

Effects and mechanisms of Helicobacter pylori on cancers development and immunotherapy

Provisionally accepted
Xiaotian Zhong Xiaotian Zhong 1,2Huiling Zheng Huiling Zheng 3Shiqing Zhao Shiqing Zhao 1,2Ziye Wang Ziye Wang 1,2Yi Su Yi Su 1,2Kaili Zhong Kaili Zhong 4*Mopei Wang Mopei Wang 5*Yanyan Shi Yanyan Shi 1*
  • 1 Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, Beijing, China
  • 2 Health Science Centre, Peking University, Beijing, Beijing Municipality, China
  • 3 Department of Gastroenterology, Peking University Third Hospital, Beijing, China
  • 4 Department of Lymphatic Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
  • 5 Peking University Third Hospital, Haidian, Beijing Municipality, China

The final, formatted version of the article will be published soon.

    Tumor immunotherapy has been widely used in clinical treatment of various cancers. However, some patients of these cancers do not respond to immunotherapy effectively. And H. pylori infection has been considered to be related to the efficacy of immunotherapy. This review aims to summarize the different effects and mechanisms of H. pylori infection on immunotherapy in different kinds of cancers. We searched the relevant literature on H. pylori and tumor immunotherapy, and summarized to form a review. Generally, H. pylori infection plays a role in affecting kinds of cancers’ development, besides gastric cancer. Current evidence suggests that H. pylori infection may reduce the efficacy of immunotherapy for colorectal cancer, non-small cell lung cancer and melanoma, but due to the lack of sufficient evidence, more data is needed to prove that. While for gastric cancer, the effects remain controversial. The H. pylori regulation effects and metabolisms involved in systematic related cancers should be paid attention to. Whether H. pylori should be eradicated when immunotherapy performed may be a critical consideration for some kinds of tumors.

    Keywords: Helicobacter pylori, Immunotherapy, gastric cancer, colorectal cancer, Melanoma, Non-small cell lung cancer

    Received: 23 Jul 2024; Accepted: 23 Sep 2024.

    Copyright: © 2024 Zhong, Zheng, Zhao, Wang, Su, Zhong, Wang and Shi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Kaili Zhong, Department of Lymphatic Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
    Mopei Wang, Peking University Third Hospital, Haidian, 100191, Beijing Municipality, China
    Yanyan Shi, Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, 100191, Beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.